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EXTENDED REPORT
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Background/aim: Involvement of programmed death-1 (PD-1) and its ligands has been demonstrated in
experimental allergic airway disease. Here, the authors aimed to examine whether PD-1 and its ligands
are involved in the development of experimental allergic conjunctivitis (EC) in mice.
Methods: EC was induced in Balb/c mice by active immunisation with short ragweed pollen (RW) in alum.
10 days later (day 10), the mice were challenged with eye drops containing RW. 24 hours after the
challenge, conjunctivas, spleens, and sera were harvested for histological analysis, cytokine assays, and
measurement of RW specific Ig levels. The actively immunised mice were treated with anti-PD-1, anti-PD-
L1, anti-PD-L2 antibodies (Abs), or normal rat immunoglobulin G (nrIgG) during either the induction (day
0, 2, 4, 6, and 8) or the effector (2 hours before RW challenge on day 10) phase.
Results: Ab treatment during the induction phase did not affect eosinophil infiltration although immune
responses were modulated. In contrast, treatment with anti-PD-L2 Ab, but not anti-PD-1 or anti-PD-L1 Ab,
during the effector phase significantly increased eosinophil infiltration into the conjunctiva without affecting
systemic immune responses.
Conclusions: Similar to allergic airway inflammation, PD-L2 is involved in the development of EC during
the effector phase but not the induction phase.
T
he severity of eosinophil infiltration into the conjunctiva
parallels the clinical severity of allergic conjunctivitis
(AC), because more eosinophils infiltrate into the
conjunctiva in patients with severe types of AC such as
vernal keratoconjunctivitis (VKC)1 and atopic keratoconjunc-
tivitis (AKC).2 In addition to eosinophils, T cells may be
involved in the development of VKC, since many CD4+ T cells
infiltrate the conjunctiva of active VKC patients.3 4
Furthermore, the observations indicating that infiltrating T
cells produce cytokines in the conjunctiva5 6 suggest that T
cells exert their effects at the inflammatory site, conjunctiva.
Mechanistic analyses using rats and mice have confirmed
that Ag specific CD4+ T cells play a crucial part in the
development of experimental AC (experimental immune
mediated blepharoconjunctivitis, EC) in terms of eosinophil
infiltration into the conjunctiva.7–9 Immunohistochemical
analyses of conjunctivas from rats8 and mice9 developing
EC demonstrated that eosinophils and T cells predominantly
infiltrated into the conjunctiva, thus resembling the con-
junctivas in VKC patients.2–4 Additional analyses using
transgenic and knockout mice have confirmed that Th2 type
T cells are putatively involved in the development of EC.10
Activation of naive T cells requires the signals from both
the T cell receptor and co-stimulatory molecules.11 Because
EC is mediated by CD4+ T cells and since activation of T cells
is required for EC development, we have investigated the
involvement of several co-stimulatory molecules in the
development of EC. With regard to proteins within the
tumour necrosis factor (TNF) receptor superfamily, a forced
stimulation of 4-1BB by intraperitoneal injection of agonistic
anti-4-1BB Ab inhibited EC,12 while injection of agonistic
anti-OX40 Ab exacerbated EC.13 In contrast, blockade of B7
related protein 1 (B7RP-1), which is a member of the B7
family and the ligand of inducible co-stimulator (ICOS), did
not affect the severity of EC.14 Thus, each co-stimulatory
molecule is involved differently in the development of EC.
Programmed death-1 (PD-1) is a member of an immu-
noglobulin (Ig) superfamily member and is related to CD28
and cytotoxic T lymphocyte associated antigen-4 (CTLA-4).15
PD-1 is expressed on activated, but not resting, CD4+ and
CD8+ T cells, on B cells and on myeloid cells.16 17 Initially, PD-
1 was identified as being involved in programmed cell death
of a T cell hybridoma.16 However, subsequent studies have
not supported a direct role in cell death. For example, a recent
study indicated that PD-1 ligand induced PD-1 expressing
cells to arrest the cell cycle in G0/G1.18 Two members of the
B7 family, PD-L1 (B7-H1) and PD-L2 (B7-DC), have been
identified to be the ligands for PD-1.19 PD-L1-Ig fusion
protein in vitro inhibits proliferation and cytokine production
of both resting and previously activated T cells.20
Furthermore, proliferation of PD-1 deficient T cells was not
inhibited by PD-L1-Ig fusion proteins, indicating that
stimulation through PD-1 provides a negative signal to T cell
activation.20 Thus, it may be that PD-1 is a negative regulator
of the development of EC, which is mediated by CD4+ T cells.
In this study, we investigated the involvement of PD-1 and its
ligands in the development of EC.
MATERIALS AND METHODS
Mice
Inbred Balb/c mice (Japan SLC Inc, Hamamatsu, Shizuoka,
Japan) were kept in specific pathogen free conditions at the
animal facility of Kochi Medical School; 6–12 weeks old
female mice were used in these studies. All research adhered
to the Association for Research in Vision and Ophthalmology
statement for the use of animals in ophthalmic and vision
research.
Abbreviations: Abs, antibodies; AC, allergic conjunctivitis; AKC, atopic
keratoconjunctivitis; ALP, alkaline phosphatase; B7RP-1, B7 related
protein 1; CTLA, cytotoxic T lymphocyte associated antigen; EC,
experimental allergic conjunctivitis; ICOS, inducible co-stimulator;
nrIgG, normal rat immunoglobulin G; PBS, phosphate buffered saline;
PD, programmed death; PD-L2, programmed death-ligand 2; RW,
ragweed pollen; TNF, tumour necrosis factor; VKC, vernal
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Reagents
Short ragweed pollen (RW) was purchased from
Polysciences, Inc (Warrington, PA, USA). RW extract was
obtained from LSL Co Ltd (Tokyo, Japan). Aluminium
hydroxide (alum) was purchased from Sigma (St Louis,
MO, USA). Antagonistic anti-PD-1 mAb (RMP1-14, rat
IgG2a),21 anti-PD-L1 mAb (MIH6, rat IgG2a),21–23 and anti-
PD-L2 mAb (TY25, rat IgG2a)21 22 Abs were prepared as
described previously and were purified from ascitic fluid
using a Protein G column. The preparations contained less
than 100 pg endotoxin/ml. Normal rat IgG (nrIgG) was
purchased from MP Biomedicals Inc (Aurora, OH, USA).
EC induction by active immunisation and treatment
with Abs
RW adsorbed on alum was injected into the left hind footpad
and at the base of the tail. A volume of 50 ml of the emulsion
(50 mg of RW and 2 mg of alum) was injected into each site.
The mice were injected intraperitoneally with 200 mg of
purified anti-PD-1, anti-PD-L1, anti-PD-L2 Ab, or control rat
IgG (n = 10 per group) on days 0, 2, 4, 6, and 8 after RW
immunisation. On day 10, the eyes of the immunised mice
were challenged with RW in PBS (2 mg in 10 ml per eye). In a
separate experiment, the actively immunised mice (n = 10
per group) were injected intraperitoneally with 200 mg of
each Ab on day 10 only, 2 hours before RW challenge. Twenty
four hours after the RW challenge, the eyes, sera, and spleens
were harvested for histological analysis, measurement of RW
specific Ig levels, and cytokine assays, respectively.
Histological analysis
The eyes, including the conjunctivas, were harvested along
with the lid margin by cutting with razor blades and scissors,
and then fixed in 10% buffered formalin. Vertical 2 mm thick
sections were cut and stained with Giemsa. Infiltrating
eosinophils in the lamina propria mucosae of the tarsal and
bulbar conjunctivas in the entire section were counted by two
observers given blind samples. The sections counted were
those from the central portion of the eye, which included the
pupil and optic nerve head. Data are expressed as infiltrating
eosinophil numbers per section. Since the counts vary
depending on the severity of inflammation (when inflamma-
tion is severe, the thickness of lamina propria mucosae
increases), the cell count data are expressed as infiltrating
eosinophil numbers divided by area (mm2) as measured by
Scion Image (Scion Corporation, Frederick, MD, USA). The
data were presented as an average (SEM) of all the mice
examined.
Measurement of cytokines in the culture supernatants
RBC depleted splenocytes (107 cells/ml) were cultured for
48 hours with RW extract (25 mg/ml) in 96 well flat bottom
plates in a final volume of 0.2 ml RPMI 1640 medium
supplemented with 10% fetal calf serum (FCS, ICN
Biomedical Japan Co, Tokyo, Japan), 2-mercaptoethanol (2-
ME, 561025 M), L-glutamine (2 mM), penicillin (100 U/ml),
and streptomycin (100 mg/ml). The levels of IL-4, IL-5, IL-10,
IL-13, and IFN-c in the culture supernatants were measured
with commercially available ELISA kits (Duoset; R&D
Systems, Minneapolis, MN, USA) according to the manu-
facturer’s recommendations.
Measurement of RW specific Igs in serum
Twenty four hours after RW challenge, blood was collected
and serum was prepared. RW specific Ig levels in serum were
assessed by ELISA. Briefly, EIA plates (Costar, Corning, NY,
USA) were coated with RW extract (1 mg/ml) at 4 C˚
overnight. After blocking with 1% bovine serum albumin in
phosphate buffered saline (PBS), serum samples were added
and incubated for 2 hours at room temperature or overnight
at 4 C˚. As the control, the quantified RW specific IgE and
pooled hyperimmune serum were used. The plates were
washed with PBS plus 0.05% Tween 20 (PBS/T) (Wako,
Osaka, Japan) and incubated for 2 hours at room tempera-
ture with alkaline phosphatase (ALP) conjugated goat Ab
specific for IgG1 or IgG2a (Zymed, San Francisco, CA, USA).
In the case of IgE, biotin conjugated rat anti-mouse IgE (BD
Biosciences, Franklin Lakes, NJ, USA) was added to each well
for 2 hours at room temperature. After washing, avidin-ALP
(Sigma) was added to each well for 1 hour. After washing
with PBS/T, p-nitrophenyl phosphate (p-nitrophenyl phos-
phate liquid substrate system, Sigma) was added to each well
and allowed to develop for 15 minutes Absorbance was
measured at 405 nm. IgG1 and IgG2a concentrations were
expressed as units (U)/ml relative to the pooled hyperim-
mune serum, while IgE concentrations were shown as ng/ml.
Immunohistochemistry
Sections were prepared for immunohistochemistry by follow-
ing the previously described method.8 In brief, the eyes from
naive or actively immunised mice that were developing EC
without Ab treatment were immediately frozen in 3%
carboxymethyl cellulose (CMC) gel. Sections 4 mm thick
were prepared and fixed in methanol. Endogenous perox-
idase activity was inhibited by incubation with 0.1% NaN3
and 0.3% H2O2 in distilled water for 10 minutes at room
temperature. The samples were then exposed to anti-PD-L2
(TY25) for 30 minutes and subsequently to biotinylated anti-
rat Abs for another 30 minutes. As a negative control,
samples were incubated with secondary Abs (biotinylated
anti-rat Abs) without exposing to anti-PD-L2 Ab. All slides
were subjected to an avidin-biotin-complex kit (Vector
laboratories Inc, USA) and then developed with 3,39-
diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO,
USA).
Statistical analysis
Significant differences in serum Ig levels, cytokine produc-
tion, and infiltrating eosinophil numbers between the Ab
Figure 1 Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab
during the induction phase did not affect eosinophil infiltration into the
conjunctiva. Balb/c mice were immunised with RW in alum. Ten days
later (day 10), the mice were challenged with RW in eye drops and their
conjunctivas were harvested 24 hours later for histological analysis by
Giemsa staining. The mice were intraperitoneally injected with nrIgG,
anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab during the induction phase
(200 mg per injection on days 0, 2, 4, 6, and 8). The infiltrating
eosinophils were counted and the data are expressed as eosinophils per
mm2 (n = 10 per group).
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treated and nrIgG treated groups were determined by
Student’s t test. p Values less than 0.05 were considered
significant.
RESULTS
Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2
Ab during the induction phase did not affect the
infi ltration of eosinophils into the conjunctiva
To investigate whether PD-1, PD-L1, or PD-L2 is involved in
the development of EC during the induction phase, actively
immunised mice were intraperitoneally injected with each Ab
every other day from days 0 to 8. There were no significant
differences in the numbers of infiltrating eosinophils into the
conjunctiva among the four groups (fig 1).
Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2
Ab during the induction phase affected both cellular
and humoral immune responses
Since Ab treatment did not affect eosinophil infiltration into
the conjunctiva, compared to the nrIgG treatment, we
conducted control studies to exclude the possibility that the
treatment with Abs exerted no effects. We evaluated both
cellular and humoral immune responses. Treatment with
anti-PD-1, anti-PD-L1 or anti-PD-L2 Abs significantly
increased IL-4, IL-5, IL-10, and IL-13 production by spleno-
cytes in response to the RW stimulation in vitro, especially
when anti-PD-L2 Ab was injected (fig 2A). RW specific IgE
levels in serum were not significantly different among the
four groups, while RW specific IgG1 and IgG2a levels were
significantly upregulated by treatment with anti-PD-L2 Ab
(fig 2B). Thus, the treatment with anti-PD-1, anti-PD-L1, or
anti-PD-L2 Ab significantly affected systemic immune
responses.
Treatment with anti-PD-L2 Ab during the effector
phase increased eosinophil infil tration into the
conjunctiva without significantly affecting systemic
immune responses
To investigate whether PD-1, PD-L1, or PD-L2 is involved in
the development of EC during the effector phase, actively
Figure 2 Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab during induction phase affected systemic immune responses. Spleens and sera were
collected at the time of harvesting the conjunctivas from actively immunised mice treated with nrIgG, anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab during the
induction phase as described in the legend to figure 1. The IL-4, IL-5, IL-10, IL-13, and IFN-c levels in the culture supernatants of splenocytes stimulated
with RW were measured by ELISA (A). RW specific IgE, IgG1, and IgG2a levels were evaluated by ELISA (B). *p,0.05, **p,0.01, compared with
nrIgG treated group.
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immunised mice were intraperitoneally injected with each Ab
on day 10, 2 hours before RW challenge. Anti-PD-L2 Ab
treatment significantly increased eosinophil infiltration
(fig 3). Analyses of RW specific cytokine production (fig 4A)
and RW specific Ig levels (fig 4B) demonstrated that no
significant differences were observed among the four groups.
PD-L2 expression in the conjunctiva was upregulated
by the induction of EC
Finally, to confirm the expression of PD-L2 in the con-
junctiva, conjunctivas from naive and EC developing mice
were harvested for immunohistochemical analysis. A small
number of PD-L2 expressing cells were detected in the
conjunctiva of naive mice (fig 5A). In contrast, PD-L2
expressing cells were increased by the induction of EC
(fig 5B). Negative controls did not show any positive signals
(data not shown).
DISCUSSION
In murine experimental asthma, the involvement of PD-1
and its ligands has been demonstrated.21 Consistent with this
previous report demonstrating that treatment with anti-PD-1
Ab did not affect asthmatic responses,21 we show here that
treatment with anti-PD-1 Ab had no effect on EC during
Figure 3 Treatment with anti-PD-L2 Ab during the effector phase
increased eosinophil infiltration into the conjunctiva. Balb/c mice were
immunised with RW in alum. Ten days later (day 10), the mice were
challenged with RW in eye drops and their conjunctivas were harvested
24 hours later for histological analysis by Giemsa staining. The mice
were intraperitoneally injected with 200 mg of nrIgG, anti-PD-1, anti-PD-
L1, or anti-PD-L2 Ab during the effector phase on day 10, 2 hours
before RW challenge. The infiltrating eosinophils were counted and the
data are expressed as eosinophils per mm2 (n = 10 per group).
*p,0.05, compared with nrIgG treated group.
Figure 4 Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab during the effector phase did not significantly affect systemic immune responses.
Spleens and sera were collected at the time of harvesting the conjunctivas from actively immunised mice treated with nrIgG, anti-PD-1, anti-PD-L1, or
anti-PD-L2 Ab during the effector phase as described in the legend to figure 3. The IL-4, IL-5, IL-10, IL-13, and IFN-c levels in the culture supernatants of
splenocytes stimulated with RW were measured by ELISA (A). RW specific IgE, IgG1, and IgG2a levels were evaluated by ELISA (B).
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either the induction or the effector phase. In contrast,
treatment with anti-PD-L2 Ab during the effector phase
increased inflammation in the lung,21 a result in good
agreement with our observation that anti-PD-L2 Ab
treatment during the effector phase increased eosinophil
infiltration into the conjunctiva. It has also been reported
that injection of murine PD-L2-Fc fusion protein increased
cell infiltration to bronchoalveolar lavage fluid.24 Recent
studies have shown that PD-L2-Fc binds and co-stimulates
naive CD4+ T cells from PD-1 deficient mice.25 26 Thus, our
data further support the possibility that PD-L2 interacts not
only with PD-1 but also with some receptor other than PD-1.
Treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 Ab
during the induction phase significantly affected RW specific
immune responses. Particularly, treatment with anti-PD-L2
Ab markedly increased RW specific Th2 cytokine production
and RW specific IgGs in serum. However, these changes in
immune responses did not affect eosinophil infiltration into
the conjunctiva. It remains unclear why the upregulated Th2
immune responses (IL-4, IL-5, and IL-13) did not affect the
eosinophil infiltration. It is of note that IL-10, which
regulates allergic reactions,27 was also upregulated in the
anti-PD-L2 Ab treated group and the upregulation of IL-10
might have suppressed the effector function of Th2 immune
responses. Further study will be necessary to elucidate the
role of IL-10 in the development of EC.
Importantly, the upregulation of eosinophil infiltration by
the treatment with anti-PD-L2 Ab was noted during the
effector phase but not the induction phase indicating that the
interaction between PD-L2 and its putative receptor other than
PD-1 is important for the recruitment of eosinophils into the
conjunctiva. In fact, using immunohistochemical methods, we
found that expression of PD-L2 in the conjunctiva was
upregulated by the induction of EC. Although we have not
examined which types of cells express PD-L2 in the con-
junctiva, it was reported that expression of PD-L2 is restricted
in macrophages and dendritic cells.28 Thus, the interaction
between PD-L2 presumably expressed in macrophages and
dendritic cells and its receptor occurring in the conjunctiva is
likely to be involved in eosinophil infiltration. Thus, PD-L2 may
be a therapeutic candidate for the inhibition of eosinophil
infiltration into the conjunctiva in severe AC.
ACKNOWLEDGEMENTS
We thank Ms Waka Ishida and Kazuyo Fukata for their excellent
technical help. This work was supported in part by grant in aid for
scientific research from the Ministry of Education, Culture, Sports,
Science, and Technology, Japan (AF).
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
A Fukushima, T Yamaguchi, H Ueno, Department of Ophthalmology,
Kochi Medical School, Kochi University, Japan
M Azuma, Department of Molecular Immunology, Graduate School,
Tokyo Medical and Dental University, Tokyo, Japan
H Yagita, Department of Immunology, Juntendo University School of
Medicine, Japan
REFERENCES
1 Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a
case series of 195 patients with long-term followup. Ophthalmology
2000;107:1157–63.
2 Fukagawa K, Nakajima T, Tsubota K, et al. Presence of eotaxin in tears of
patients with atopic keratoconjunctivitis with severe corneal damage. J Allergy
Clin Immunol 1999;103:1220–1.
3 Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye
disease. J Allergy Clin Immunol 1997;100:817–24.
4 Avunduk AM, Avunduk MC, Dayanir V, et al. A flow cytometric study about
the immunopathology of vernal keratoconjunctivitis. J Allergy Clin Immunol
1998;101:821–4.
5 Leonardi A, DeFranchis G, Zancanaro F, et al. Identification of local Th2 and
Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest
Ophthalmol Vis Sci 1999;40:3036–40.
6 Matsuura N, Uchio E, Nakazawa M, et al. Predominance of infiltrating IL-4-
producing T cells in conjunctiva of patients with allergic conjunctival disease.
Curr Eye Res 2004;29:235–43.
7 Fukushima A, Fukata K, Ozaki A, et al. Exertion of the suppressive effects of
IFN-c on experimental immune mediated blepharoconjunctivitis in brown
Norway rats during the induction phase but not the effector phase.
Br J Ophthalmol 2002;86:1166–71.
8 Fukushima A, Ozaki A, Fukata K, et al. Ag-specific recognition, activation,
and effector function of T cells in the conjunctiva with experimental immune-
mediated blepharoconjunctivitis. Invest Ophthalmol Vis Sci
2003;44:4366–74.
9 Fukushima A, Yamaguchi T, Ishida W, et al. Genetic background determines
susceptibility to experimental immune-mediated blepharoconjunctivitis:
comparison of Balb/c and C57BL/6 mice. Exp Eye Res (in press).
10 Ozaki A, Seki Y, Fukushima A, et al. The control of allergic conjunctivitis by
suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model.
J Immunol 2005;175:5489–97.
11 June CH, Ledbetter JA, Gillespie MM, et al. T-cell proliferation involving the
CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene
expression. Mol Cell Biol 1987;7:4472–81.
12 Fukushima A, Yamaguchi T, Ishida W, et al. Engagement of 4-1BB inhibits the
development of experimental allergic conjunctivitis in mice. J Immunol
2005;175:4897–903.
13 Fukushima A, Yamaguchi T, Ishida W, et al. Roles of OX40 in the
development of murine experimental allergic conjunctivitis: exacerbation and
attenuation of eosniophil infiltration by stimulation and blocking of OX40.
Invest Ophthalmol Vis Sci (in press).
14 Fukushima A, Yamaguchi T, Ishida W, et al. The interaction between ICOS
and B7RP-1 is not required for the development of experimental murine
allergic conjunctivitis. Biochem Biophys Res Commun 2005;338:1726–31.
15 Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel
member of the immunoglobulin gene superfamily, upon programmed cell
death. EMBO J 1992;11:3887–95.
16 Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on
the surface of stimulated mouse T and B lymphocytes. Int Immunol
1996;8:765–72.
A B
Figure 5 PD-L2 expression in the conjunctiva was upregulated by the induction of EC. Conjunctivas from naive (A) and EC developing mice (B) were
harvested for immunohistochemical analysis using anti-PD-L2 Ab (TY25). PD-L2 expressing cells were detected in the conjunctiva of naive mice (A). By
induction of EC, PD-L2 expressing cells increased in the conjunctiva (B). Bar = 20 mm. One representative of four mice is shown. Arrows indicate Ab
stained cells.
1044 Fukushima, Yamaguchi, Azuma, et al
www.bjophthalmol.com
 group.bmj.com on March 1, 2010 - Published by bjo.bmj.comDownloaded from 
17 Vibhakar R, Juan G, Traganos F, et al. Activation-induced expression of
human programmed death-1 gene in T-lymphocytes. Exp Cell Res
1997;232:25–8.
18 Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1
and inhibits T cell activation. Nat Immunol 2001;2:261–8.
19 Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev
Immunol 2005;23:515–48.
20 Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both
CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol
2002;32:634–43.
21 Matsumoto K, Inoue H, Nakano T, et al. B7-DC regulates asthmatic
response by an IFN-gamma-dependent mechanism. J Immunol
2004;172:2530–41.
22 Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed
death 1 ligands by murine T cells and APC. J Immunol
2002;169:5538–45.
23 Tsushima F, Iwai H, Otsuki N, et al. Preferential contribution of B7-H1 to
programmed death-1-mediated regulation of hapten-specific allergic
inflammatory responses. Eur J Immunol 2003;33:2773–82.
24 Oflazoglu E, Swart DA, Anders-Bartholo P, et al. Paradoxical role of
programmed death-1 ligand 2 in Th2 immune responses in vitro and in a
mouse asthma model in vivo. Eur J Immunol 2004;34:3326–36.
25 Wang S, Bajorath J, Flies DB, et al. Molecular modeling and functional
mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1
interaction. J Exp Med 2003;197:1083–91.
26 Shin T, Kennedy G, Gorski K, et al. Cooperative B7-1/2 (CD80/CD86) and
B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp
Med 2003;198:31–8.
27 Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation
of allergic immune responses. Int Arch Allergy Immunol 2001;126:97–101.
28 Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev
Immunol 2005;23:515–48.
Video reports
To view the video reports in full visit http://bjo.bmjjournals.com/video/collection.dtl.
N Ocular motor apraxia. TN Win, DE Laws
N Bimanualirrigation and aspiration with no instrument exchange. YC Lee, MW Lee
N Intrusion of an encircling band with recurrent retinal detachment: surgical approach.
E Doyle, I Georgalas, P Sullivan, DAH Laidlaw
N Dissection of the trabeculectomy bleb pocket using a novel dissecting instrument.
EZ Blumenthal
N Dynamic ultrasound movements of the eye and orbit. JPS Garcia Jr, PMT Garcia, PT Finger
N Iris cerclage suture technique for traumatic mydriasis. LE Ferna´ndez de Castro,
HP Sandoval, KD Solomon, DT Vroman
N Lamellar keratoplasty and intracorneal inlay: An alternative to corneal tattooing and
contact lenses for disfiguring corneal scars. EJ Hollick, A Coombes, JJ Perez-Santonja,
JKG Dart
N A case report of pulsating exophthalmos. D Sahu, N Maycock, A Booth
Roles of PD-L2 in mouse allergic conjunctivitis 1045
www.bjophthalmol.com
 group.bmj.com on March 1, 2010 - Published by bjo.bmj.comDownloaded from 
